Interactive I-O Pathway Wheel

April 13, 2018
R
esearch in Immuno-Oncology at Bristol-Myers Squibb is focused on discovering ways to leverage the complex tumor microenvironment to reset and optimize antitumor activity.
 
 
 
 
 
Effector cells are central to antitumor immunity. Effector cell antitumor activity can be held in check by three ways that exploit normal immune mechanisms.

Tumor
The TUMOR may leverage inherent mechanisms to sustain itself and evade immune destruction.

Stroma
The STROMA comprises a variety of cell types that may suppress immune function via expression of cell surface or soluble inhibitory molecules, including metabolites.

Immune regulatory cells & APCs
IMMUNE REGULATORY and ANTIGEN PRESENTING CELLS may negatively regulate or not provide necessary stimulation in the immune system.

Through our deep understanding of immunobiology, we have focused on multiple categories of immune mechanisms that can help restore the body’s natural ability to fight cancer.

We’re investigating multiple approaches in each category. As most tumors use more than one immune suppression mechanism or develop new mechanisms over the course of the disease, we continue to investigate how signaling pathways interact and work to identify combination strategies that may activate an effective immune response.

Select a mechanism name for more information.

Select a mechanism name for more information.

Select a mechanism name for more information.

GITR

References

CD137

References

CD27

References

OX40

References

ICOS

References

KIR

References

SLAMF7

References

CXCR4

References

BCR-ABL

References

BET

References

PD-1

References

CTLA-4

References

TIM-3

References

TIGIT

References

LAG 3

References

CCR2/5

References

IL-8

References

Viruses

References

IDO

References

CCR4

References

CD73

References

CTLA-4-NF

References

TGFβ

References

CSF1R

References